Pharmaceutical composition for use in a method of treating a cancerous disease, the method comprising reducing or inhibiting the migration or metastasis of tumor cells, which are identified by the expression of a tumor associated antigen, and comprising the pharmaceutical composition one or more components selected from the group consisting of: (i) a tumor associated antigen or a part thereof, (ii) a nucleic acid, which encodes a tumor associated antigen or a part thereof , (iii) an antibody, which binds to a tumor-associated antigen or part of it, and (iv) an antisense nucleic acid, which hybridizes under stringent conditions specifically to a nucleic acid, which encodes an antigen associated with a tumor, in which the part comprises at least 6 consecutive amino acids of the tumor associated antigen, in which the tumor associated antigen has a sequence, which is encoded by a nucleic acid which is selected from the group consisting of: (a) a nucleic acid, which comprises a nucleic acid sequence, which is selected from the group consisting of SEQ ID NO: 19 -21 and 54-57, and (b) a nucleic acid, which has at least 90% sequence identity with the nucleic acid of (a).Composición farmacéutica para su utilización en un procedimiento para el tratamiento de una enfermedad cancerosa, comprendiendo el procedimiento la reducción o la inhibición de la migración o la metástasis de células tumorales, que se identifican por la expresión de un antígeno asociado a un tumor, y comprendiendo la composición farmacéutica uno o varios componentes seleccionados de entre el grupo constituido por: (i) un antígeno asociado a un tumor o una parte del mismo, (ii) un ácido nucleico, que codifica un antígeno asociado a un tumor o una parte del mismo, (iii) un anticuerpo, que se une a un antígeno asociado a un tumor o a una parte del mismo, y (iv) un ácido nucleico antisentido, que se hibrida en condiciones rigurosas específicamente con un ácido nucleico, que codifica un antígeno asociado a un tum
